6-hydroxydopa has been researched along with Parkinson Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, D; Liu, H; Liu, J; Liu, Y; Wang, J; Zhao, Z | 1 |
| Alter, H; Domanskyi, A; Gass, P; Geissler, C; Parlato, R; Schober, A; Schütz, G; Vinnikov, IA; Vogt, MA | 1 |
| Borsini, F; Morelli, M; Pinna, A; Pontis, S | 1 |
| Facci, L; Fadda, E; Manev, H; Skaper, SD | 1 |
| Kannari, K; Matsunaga, M; Shen, H; Suda, T; Yamato, H | 1 |
| Dal Toso, R; Facci, L; Leon, A; Moroni, F; Schiavo, N; Skaper, SD; Vantini, G | 1 |
| Labruyere, J; Olney, JW; Price, MT; Stewart, GR; Wang, GJ; Zorumski, CF | 1 |
7 other study(ies) available for 6-hydroxydopa and Parkinson Disease
| Article | Year |
|---|---|
Regulation of Actg1 and Gsta2 is possible mechanism by which capsaicin alleviates apoptosis in cell model of 6-OHDA-induced Parkinson's disease.
Topics: Actins; Animals; Antiparkinson Agents; Apoptosis; Capsaicin; Cell Line, Tumor; Dihydroxyphenylalanine; Disease Models, Animal; Gene Expression Regulation; Glutathione Transferase; Humans; Isoenzymes; Neurons; Parkinson Disease; Rats; Signal Transduction; Substantia Nigra | 2020 |
Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Dopamine Agents; Gene Deletion; Gene Expression Regulation; Mice; Mice, Knockout; Neurons; Parkinson Disease; Pol1 Transcription Initiation Complex Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; TOR Serine-Threonine Kinases; Tyrosine 3-Monooxygenase | 2011 |
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Dihydroxyphenylalanine; Dopamine Agents; Functional Laterality; Immunohistochemistry; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Triazoles; Tyrosine 3-Monooxygenase; Vibrissae | 2007 |
A semisynthetic glycosphingolipid (LIGA20) reduces 2,4, 5-trihydroxyphenylalanine neurotoxicity in primary neuronal cultures.
Topics: Animals; Cells, Cultured; Cerebellum; Dihydroxyphenylalanine; G(M1) Ganglioside; Glycosphingolipids; Neurons; Parkinson Disease; Rats; Sphingosine | 1993 |
Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Extracellular Space; Fluoxetine; Levodopa; Male; Parkinson Disease; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2001 |
Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cells, Cultured; Cerebellum; Dihydroxyphenylalanine; G(M1) Ganglioside; Mesencephalon; MPTP Poisoning; Oxidation-Reduction; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley | 1992 |
Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Chick Embryo; Dibenzocycloheptenes; Dihydroxyphenylalanine; Dizocilpine Maleate; Hippocampus; Huntington Disease; Levodopa; Neurons; Parkinson Disease; Quinoxalines; Receptors, Neurotransmitter; Retina | 1990 |